Serum Levels of Vimentin and Oxyntomodulin in Women with Breast Cancer. Comparative Study
DOI:
https://doi.org/10.61841/ejfwww53Keywords:
Breast cancer,, Vimentin, OxyntomodulinAbstract
Background: Breast cancer is the most frequent malignancy among women worldwide, accounting for 25
% of all cancers.(1) The incidence rates of breast cancer have been increasing almost in all countries to reach more than two million cases in 2018.(2) Vimentin (VIM), is a 57 KDa protein is one of the most widely expressed and highly conserved proteins of the type III intermediated filament protein family.(3) VIM plays a significant role in holding the organelles in the cytosol it has a flexible nature, allowing it to respond to mechanical stress and by interacting with other structural proteins, like microtubules, it makes the cell rigid and sturdy.(4) Oxyntomodulin (OXM) is a 44.499 KDa peptide hormone produced by the neuroendocrine cells of the ileum.(5) Oxyntomodulin characterized by, ability to interact with and modulate the gastric oxyntic gland.(6)
Materials & Methods: This is a cross sectional hospital based study. This study was carried out at the Oncology Center in Kirkuk City-Iraq from the1st of November 2019 to the end of May 2020. Forty-five women with breast cancer were considered as a study group. Forty-tow apparently healthy women without breast cancer and with a negative family history for the first and second degree relatives of breast cancer were consider as a control group. By using a sterile disposable syringe 5 mls of venous blood sample was drawn from each woman and was kept in a plain tube and allowed to clot at room temperature, then each sample was centrifuged at 3000 rpm to obtain serum. Serum of the patients and controls had assay for Vimentin and Oxyntomodulin by ELISA.
Results: The mean serum level of vimentin was significantly higher in women with breast cancer compared to control at a P value of 0.006, while the mean serum level of oxyntomodulin was lower in women with breast cancer as compared with the control group, this result was highly significant at a P value of 0.003. This study found that there was a negative correlation between S.OXM and S. VIM level in breast cancer women (r = -0.135).
Conclusion: This study reveals that there was a negative correlation between S.OXM and S. VIM level in breast cancer women r = -0.135.
Downloads
References
1. Fitzmaurice, Christina, et al. "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study." JAMA oncology 3.4 (2017): 524-548
2. Conti, Allegra, et al. "Radiomics in breast cancer classification and prediction." Seminars in Cancer Biology. Academic Press, 2020.
5. Sharma P, Alsharif S, Fallatah A, Chung BM. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. Cells. 2019 May;8(5):497.
4. Etienne-Manneville S. Cytoplasmic intermediate filaments in cell biology. Annual review of cell and developmental biology. 2018 Oct 6;34:1-28.
5. Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CA, Parker HE, Morley TC, Yeo GS, Reimann F, Gribble FM. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology. 2012 Jul 1;153(7):3054-65.
6. Ahmed M, Ahmed S. Functional, Diagnostic and Therapeutic Aspects of Gastrointestinal Hormones. Gastroenterology research. 2019 Oct;12(5):233.
7. Kerin-Ayres, Kim, and Meagan E. Brennan. "An Australian–Sri Lankan partnership: Fostering the development of the breast care nurse role." Australian Nursing and Midwifery Journal 26.9 (2020): 47-47.
8. Rusby J, Agha R. N
ipple and breast anatomy. InOperative Approaches to Nipple-Sparing Mastectomy 2017 (pp. 11-19). Springer, Cham.
9. Anwar SL, Tanjung DS, Fitria MS, Kartika AI, Sari DN, Rakhmina D, Wardana T, Astuti I, Haryana SM, Aryandono T. Dynamic Changes of Circulating Mir-155 Expression and the Potential Application as a Non-Invasive Biomarker in Breast Cancer. Asian Pacific Journal of Cancer Prevention. 2020 Feb 1;21(2):491-7.
10. Sviripa VM, Burikhanov R, Obiero JM, Yuan Y, Nickell JR, Dwoskin LP, Zhan CG, Liu C, Tsodikov OV, Rangnekar VM, Watt DS. Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin. Organic & biomolecular chemistry. 2016;14(1):74-84.
11. Merenick BL, Beech RP, Reed TD, Tretiakova AP, Peterson RE, inventors; Intrexon Corp, assignee. Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof. United States patent US 10,314,926. 2019 Jun 11
12. Shim, Jien, and Run Yu. "Gut Hormones in Pregnancy and Lactation." Maternal-Fetal and Neonatal Endocrinology. Academic Press, 2020. 91-99.
13. Jonnakuti VS, Stanescu DE, De Leon DD. Developmental Origins and Roles of Intestinal Enteroendocrine Hormones. InMaternal-Fetal and Neonatal Endocrinology 2020 Jan 1 (pp. 599-610). Academic Press.
14. Kaberi-Otarod J, Yu YH. Role of the Gut in the Regulation of Energy Balance and Energy Stores. InBariatric Endocrinology 2019 (pp. 77-98). Springer, Cham.
15. Jaime TJ, Balich LL, Acevedo GB, de la Maza Cave MP, Birn SH, Parada SH, Silva JR, Barnett DB. Effect of calorie restriction on energy expenditure in overweight and obese adult women. Nutricion hospitalaria. 2015;31(6):2428-36.
16. Mishra S, Sharma DC, Sharma P. Studies of biochemical parameters in breast cancer with and without metastasis. Indian Journal of Clinical Biochemistry. 2004 Jan 1;19(1):71-5.
17. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. New England Journal of Medicine. 2000 Feb 24;342(8):564-71.
18. Majid, Runnak A., et al. Breast cancer in Iraq is associated with a unimodally distributed predominance of luminal type B over luminal type A surrogates from young to old age. BMC women's health, 2017,17.1:27.
19. Shrivastava V, Meena P, Nandwani R, Meena S. A study of Serum levels of LDH and ALP in carcinoma breast: An Observational study.
20 Amritpal Kaur , Mridula Mahajan and Sudhir Khichy . Biomarkers of carcinoma breast in females.
International Journal of Recent Scientific Research. 2015 ,6(2) 2625-2629.
21. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Critical reviews in oncology/hematology. 2004 Jul 1;51(1):55-67.
22. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, Garber JE. Modification of BRCA1-and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer research. 2001 Jul 15;61(14):5420-4.
23. Arko-Boham B, Lomotey JT, Tetteh EN, Tagoe EA, Aryee NA, Owusu EA, Okai I, Blay RM, Clegg- Lamptey JN. Higher serum concentrations of vimentin and DAKP1 are associated with aggressive breast tumour phenotypes in Ghanaian women. Biomarker research. 2017 Dec;5(1):21.
24. Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH. Death-associated protein kinase 1 promotes growth of p53-mutant cancers. The Journal of clinical investigation. 2015 Jul 1;125(7):2707-20.
25. youb Jung S, Jang MH, Shen LA, Park YK, Park YJ, Kwon SC, inventors; Hanmi Science Co Ltd, assignee. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same. United States patent US 9,522,946. 2016 Dec 20.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
